Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival

Lad, Deepesh; Tejaswi, V.; Jindal, Nishant; Malhotra, Pankaj; Khadwal, Alka; Prakash, Gaurav; Jain, Arihant; Sreedharanunni, Sreejesh; Sachdeva, Manupdesh Singh; Naseem, Shano; Varma, Neelam; Varma, Subhash

doi:10.1080/10428194.2020.1719099

Cited by 8 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was expected as patients with worse prognosis were already on therapy or had a shorter time to first therapy requirement than patients with lower LIPI scores. 10 In terms of therapy, patients on ibrutinib had better social functioning, lesser fatigue, appetite loss compared to patients on CIT, however, no difference in summary scores on univariate or multivariate analysis was seen. Also, patients on ibrutinib had less worries/fears about health and functioning than patients who had completed CIT.…”

Section: Impact Of Prognosis and Therapy On Qolmentioning

confidence: 87%

“…The patient's socioeconomic status (SES) was determined by the modified Kuppuswamy scale 9 . Prognostic Index (CLL‐LIPI) was calculated at baseline 10 . The quality of life (QoL) of patients was ascertained using the EORTC QLQ30 and CLL17 questionnaires in person by a physician 11,12 .…”

Section: Methodsmentioning

confidence: 99%

“…9 Prognostic Index (CLL-LIPI) was calculated at baseline. 10 The quality of life (QoL) of patients was ascertained using the EORTC QLQ30 and CLL17 questionnaires in person by a physician. 11,12 Both these questionnaires were validated in the regional Hindi language.…”

Section: Me Thodsmentioning

confidence: 99%

See 2 more Smart Citations

Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire

Youron

Singh

Jindal

et al. 2020

European J of Haematology

Self Cite

View full text Add to dashboard Cite

Despite the advances in the treatment, chronic lymphocytic leukemia (CLL) remains an incurable disease. Patient-reported outcomes like quality of life (QoL) analyses are increasingly incorporated into clinical trials. This is important where therapies that do not affect overall survival but differ by an anticipated gain in QoL are compared. 1 Besides, this also strengthens the physician-patient relationship. 2 Formal QoL analyses in CLL outside of clinical trials have been few. The most extensive international study done in 2007 was using the older QoL assessment questionnaires British Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaires. 3 Other studies using the more universally validated European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires were limited to regional analyses. 4-6 These studies have shown contradictory findings from compromised to better QoL in CLL patients than the

show abstract

Section: Impact Of Prognosis and Therapy On Qolmentioning

confidence: 87%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire

Youron

Singh

Jindal

et al. 2020

European J of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…S-β2M level and s-TK level were reported as independent predictors of progression-free survival (PFS) of CLL more than 20 years ago [11]. S-β2M was widely used to improve risk stratification and retained independent prognostic value in several multiparameter scores [12][13][14][15][16][17][18][19][20][21]. Elevated s-TK level, which relates to shorter LDT and IGHV unmutated status, indicates the high risk of CLL patients and predicts disease progression [22].…”

Section: Serum Markersmentioning

confidence: 99%

“…However, IGHV mutational status was only available in 10.1% CLL patients in 2014 in the United States [53]. Due to the correlation between LDT and IGHV mutational status, Deepesh P. Lad et al created the modified CLL International Prognostic Index (CLL-LIPI), replacing IGHV unmutated status to LDT < 6 months and maintaining the original score of CLL-IPI [18]. It shows a comparable prognosis of OS with CLL-IPI.…”

Section: Risk Staging Systems In Cllmentioning

confidence: 99%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation status, microRNAs, chromosome aberrations and gene mutations, have contributed to prognosis in CLL. Del17p/ TP53 mutation, NOTCH1 mutation, CD49d, IGHV mutation status, complex karyotypes and microRNAs were reported to be of predictive values to guide clinical decisions. Based on the biomarkers above, classic prognostic models, such as the Rai and Binet staging systems, MDACC nomogram, GCLLSG model and CLL-IPI, were developed to improve risk stratification and tailor treatment intensity. Considering the presence of novel agents, many investigators validated the conventional prognostic biomarkers in the setting of novel agents and only TP53 mutation status/del 17p and CD49d expression were reported to be of prognostic value. Whether other prognostic indicators and models can be used in the context of novel agents, further studies are required.

show abstract

How Do We Manage Chronic Lymphocytic Leukemia in India

Karunakaran,

Jain,

Lad

2024

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival

Cited by 8 publications

References 13 publications

Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire

Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

How Do We Manage Chronic Lymphocytic Leukemia in India

Contact Info

Product

Resources

About